Teva and Celltrion’s attempt to muscle in on the multi-billion dollar US cancer and inflammatory disease drug market has hit a setback after the FDA rejected two key biosimilars because of manufacturing problems. The companies filed biosimilars of...
Original Article: FDA rejects Teva/Celltrion biosimilars